STOCK TITAN

Atrion Reports Second Quarter 2024 Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Atrion (NASDAQ: ATRI) reported its Q2 2024 results, showing revenue growth of 11% to $48.8 million. However, operating income decreased significantly to $0.5 million, largely due to a $5.0 million accrual for acquisition-related expenses. Excluding this accrual, adjusted operating income was $5.5 million, down 25% year-over-year. Diluted EPS fell to $0.23 from $3.73 in Q2 2023.

The company saw strong growth in MPS consoles (22%) and disposables (21%), along with recovery in fluid delivery products. Atrion continued to reduce inventories, which negatively impacted operating income but resulted in an 18% inventory reduction since December 31, 2023. As of June 30, 2024, Atrion remained debt-free with $23.2 million in cash and investments.

Loading...
Loading translation...

Positive

  • Revenue growth of 11% to $48.8 million in Q2 2024
  • MPS consoles sales up 22% and MPS disposables sales up 21%
  • Recovery in fluid delivery products with double-digit revenue increases in certain product families
  • 18% reduction in inventory levels since December 31, 2023
  • Debt-free status maintained with $23.2 million in cash and investments

Negative

  • Operating income decreased to $0.5 million from $7.4 million in Q2 2023
  • Diluted EPS fell to $0.23 from $3.73 in Q2 2023
  • Adjusted operating income (excluding merger accrual) down 25% year-over-year
  • Halted production lines to reduce inventories, resulting in under-absorption of overhead
  • $5.0 million accrual for acquisition-related expenses impacting operating income

News Market Reaction

+0.03%
1 alert
+0.03% News Effect

On the day this news was published, ATRI gained 0.03%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the second quarter ended June 30, 2024.

Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 2023.

Commenting on the results for the second quarter of 2024 compared to the prior year period, David Battat, President and CEO, stated, “We were pleased to see strong revenue growth of 11%. Adjusting for the accrual of expenses relating to the merger with Nordson Corporation announced May 28, 2024, operating income was $5.5 million, down 25% from the prior year period. Our MPS consoles showed particularly strong growth, with sales up 22% and MPS disposables sales up 21%. We saw continued recovery in our fluid delivery products, with certain product families showing double-digit revenue increases compared to the prior year period. We continued to halt some fluid delivery production lines to reduce inventories accumulated as the result of the supply chain disruptions in 2023. While this halt resulted in under-absorption of overhead and negatively impacted operating income, the value of inventories declined 10% from the first to the second quarters of this year and are 18% lower than they were December 31, 2023.”

Mr. Battat concluded, “As of June 30, 2024, cash and short- and long-term investments totaled $23.2 million. We remain debt free.”

Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.

Contact:Cindy Ferguson
Vice President and Chief Financial Officer
(972) 390-9800

 

ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
 
 Three Months Ended
June 30,
 Six Months Ended
June 30,
  2024   2023   2024   2023 
Revenues$48,773  $43,838  $96,107  $83,831 
Cost of goods sold 32,926   26,584   67,909   51,496 
Gross profit 15,847   17,254   28,198   32,335 
Operating expenses 15,313   9,875   24,522   20,486 
Operating income 534   7,379   3,676   11,849 
        
Interest and dividend income  388    127    544    367 
Other investment income (loss)  (542)   98    (651)   (623)
Other income  23    29    37    39 
Interest expense  --    (27)   --    (27)
Income before income taxes 403   7,606   3,606   11,605 
Income tax provision (1)  (1,043)  (412)  (1,557)
Net income $402  $6,563  $3,194  $10,048 
        
Income per basic share$0.23  $3.73  $1.81  $5.71 
        
Weighted average basic shares outstanding 1,761   1,760   1,761   1,761 
        
        
Income per diluted share$0.23  $3.73  $1.81  $5.70 
        
Weighted average diluted shares outstanding 1,763   1,761   1,762   1,762 


ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
 
 June 30, Dec 31,
ASSETS2024 2023
 (Unaudited)  
Current assets:   
Cash and cash equivalents$11,462 $3,565
Short-term investments 6,124  2,691
Total cash and short-term investments 17,586  6,256
Accounts receivable 26,555  23,029
Inventories 67,641  82,307
Prepaid expenses and other 7,480  3,173
Total current assets 119,262  114,765

Long-term investments
 5,624  8,165

Property, plant and equipment, net
 122,905  125,347
Other assets 12,563  12,548
    
 $260,354 $260,825
    
    
LIABILITIES AND STOCKHOLDERS’ EQUITY   
    
Current liabilities 17,537  12,621
Other non-current liabilities 3,944  5,315
Stockholders’ equity 238,873  242,889
    
 $260,354 $260,825


ATRION CORPORATION
NON-GAAP FINANCIAL INFORMATION
(In thousands)
 

This release includes a reference to non-GAAP operating income that excludes merger-related expenses accrued in the second quarter of 2024. This financial measure is not prepared in accordance with GAAP. The operating income excluding the merger accrual is calculated by increasing operating income by the amount of the merger-related expenses.

We believe that this non-GAAP measure provides insight into our operating income performance. However, this non-GAAP financial measure may not be comparable to similarly titled non-GAAP financial measures used by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for GAAP financial measures. and are supplemental to the comparable GAAP measures.

Reconciliation to the most directly comparable GAAP measure is provided in the table below.

 Three Months Ended
June 30,
   
 2024 2023 Change 
Revenues$ 48,773 $43,838  11% 
Cost of goods sold 32,926  26,584   
Gross profit 15,847  17,254   
       
Operating income 534  7,379   
Add: merger accrual 5,000  -   
Operating income excluding merger accrual 5,534  7,379  (25%) 

FAQ

What was Atrion's revenue for Q2 2024?

Atrion (ATRI) reported revenue of $48.8 million for Q2 2024, representing an 11% increase from $43.8 million in Q2 2023.

How did Atrion's earnings per share (EPS) change in Q2 2024?

Atrion's (ATRI) diluted earnings per share (EPS) decreased to $0.23 in Q2 2024, compared to $3.73 in Q2 2023.

What impacted Atrion's operating income in Q2 2024?

Atrion's (ATRI) operating income was significantly impacted by a $5.0 million accrual for acquisition-related expenses related to the merger with Nordson announced on May 28, 2024.

How much cash and investments did Atrion have as of June 30, 2024?

As of June 30, 2024, Atrion (ATRI) reported $23.2 million in total cash and short-term and long-term investments.

What was the performance of Atrion's MPS product line in Q2 2024?

Atrion (ATRI) reported strong growth in its MPS product line, with MPS console sales up 22% and MPS disposables sales up 21% in Q2 2024 compared to the prior year period.
Atrion Corp

NASDAQ:ATRI

ATRI Rankings

ATRI Latest News

ATRI Stock Data

809.44M
1.35M
Surgical and Medical Instrument Manufacturing
Surgical & Medical Instruments & Apparatus
Link
US
ALLEN